Stealth BioTherapeutics Corp (Nasdaq: MITO) (the “Company” or “Stealth BioTherapeutics”), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, announced today the completion of the merger (the “Merger”) with Stealth Merger Sub Limited, an exempted company with limited liability incorporated under the law of the Cayman Islands (“Merger Sub”). As a result of the Merger, the Company has become a privately held company and its ADSs will no longer be listed on the NASDAQ Global Market (“NASDAQ”).
Read the full article: Stealth BioTherapeutics Corp Announces Completion of Merger //
Source: https://www.prnewswire.com/news-releases/stealth-biotherapeutics-corp-announces-completion-of-merger-301680588.html